EDAP TMS Launches Ablatherm at Guy's Hospital, London
15 December 2005 - 7:47AM
PR Newswire (US)
LYON, France, December 14 /PRNewswire-FirstCall/ -- EDAP TMS S.A.
(NASDAQ:EDAP) announced today the adoption of the Ablatherm(R) HIFU
System at Guy's & St. Thomas' NHS Foundation Hospital. Declan
Cahill, Consultant Urologist, Guy's & St. Thomas' NHS
Foundation Hospital said, "Ablatherm(R) HIFU is the most exciting
addition to the prostate cancer treatment armament. It fills
significant gaps in the comprehensive management of prostate cancer
allowing Guy's & St. Thomas' NHS Foundation Hospital to fit the
treatment to the patient's quality of life as opposed to just the
treatment." Hugues de Bantel, Chief Executive Officer of EDAP-TMS,
said, "This quality of life prostate cancer treatment with the
Ablatherm(R) HIFU is available today at Guy's & St. Thomas' NHS
Foundation Hospital. I am so pleased that a hospital that has
pioneered so many breakthroughs has endorsed the technology of
Ablatherm(R) HIFU by EDAP-TMS, who over many years developed
Ablatherm(R) HIFU technology. This prostate cancer treatment is
available at two other renowned NHS hospitals in the United
Kingdom, Stepping Hill in Manchester and Royal Marsden in London.
By the end of February 2006 this treatment will be available at
more than 13 hospitals across the United Kingdom, mostly through
our partner Mobile HIFU(TM). These 16 new Ablatherm(R) centres take
the availability of Ablatherm(R) HIFU to more than 100 hospitals
across Europe by early 2006." About EDAP TMS S.A. EDAP TMS S.A.
develops and markets Ablatherm, the most advanced and clinically
proven choice for High Intensity Focused Ultrasound (HIFU)
treatment of localized prostate cancer. HIFU treatment is shown to
be a minimally invasive and effective treatment option with a low
occurrence of side effects. The company is also developing this
technology for the treatment of certain other types of tumors. EDAP
TMS S.A. also produces and commercializes medical equipment for
treatment of urinary tract stones using Extra-corporeal Shockwave
Lithotripsy (ESWL). For more information on the Company, contact
the Investor Relations Dept by phone at +33-(0)4-78-26-40-46 or see
the Company's Web site at: http://www.edap-tms.com/. This press
release contains, in addition to historical information,
forward-looking statements that involve risks and uncertainties.
These include statements regarding the Company's growth and
expansion plans. Such statements are based on management's current
expectations and are subject to a number of uncertainties and risks
that could cause actual results to differ materially from those
described in the forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described
in the Company's filings with the Securities and Exchange
Commission. CONTACT: EDAP TMS S.A. Hugues de Bantel - Philippe
Chauveau Blandine Confort +33-4-78-26-40-46 Halliburton Investor
Relations Matt Kreps - Geralyn DeBusk +1-972-458-8000 DATASOURCE:
EDAP TMS S.A. CONTACT: CONTACT: EDAP TMS S.A., Hugues de Bantel -
Philippe Chauveau, Blandine Confort, +33-4-78-26-40-46. Halliburton
Investor Relations, Matt Kreps - Geralyn DeBusk, +1-972-458-8000
Copyright
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024